Document is current
Any future updates will be listed below
-
Authors
Dolezal, James M.
Kochanny, Sara
Dyer, Emma
Ramesh, Siddhi
Srisuwananukorn, Andrew
Sacco, Matteo
Howard, Frederick M.
Li, Anran
Mohan, Prajval
Pearson, Alexander T.
-
Funding
Funding for this research was provided by:
National Institutes of Health (K12-CA13916013, U01-CA243075)
- License Information
-
More Information
Article History
Received: 17 April 2023
Accepted: 20 March 2024
First Online: 27 March 2024
Declarations
:
: The experimental protocol and data collection plan for the University of Chicago dataset was reviewed and approved by the Biological Sciences Division / University of Chicago Medical Center Institutional Review Board (IRB #20-0238). Requirement of informed consent was waived by the Biological Sciences Division / University of Chicago Medical Center Institutional Review Board. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: ATP reports personal fees from Prelude Therapeutics Advisory Board, personal fees from Elevar Advisory Board, personal fees from AbbVie consulting, and personal fees from Ayala Advisory Board, all outside of submitted work. ATP reports stock options ownership in Privo Therapeutics. All remaining authors report no competing interests.
